Transarterial chemoembolization combined with sorafenib in treatment of middle stage hepatocellular carcinoma: Efficacy and safety
10.3724/SP.J.1008.2013.00835
- Author:
Yan QU
1
Author Information
1. Department of Hepatic Surgery I, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Sorafenib;
Therapeutic chemoembolization;
Treatment outcome
- From:
Academic Journal of Second Military Medical University
2013;34(8):835-838
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with sorafenib in treatment of patients with non-resected middle stage hepatocellular carcinoma (HCC). Methods From July 2009 to July 2011, 38 middle stage HCC patients treated with TACE plus sorafenibwere included in the TACE+ sorafenib group and the other 38 patients with similar baseline characteristics receiving TACE alone were selected in the TACE group. All the patients belonged to the Barcelona Clinic Liver Cancer (BCLC) stage B. The adverse events of the TACE+ sorafenib group and the overall survival of the two groups were analyzed. Results All the patients treated with sorafenib experienced at least one drug-related adverse event during the study, including 7 (18.4%) experienced drug-related grade 3adverse events, with no grade 4 or higher adverse events occurred. The median overall survival time was 11 months (95% CI: 7.4-14.6 months) for the TACE group and15 months (95% CI: 8.4-21.6 months) for the TACE+ sorafenib group, showing significant difference between the two groups (P=0.019). Conclusion T he combination of sorafenib with TACE is well tolerated in non-resected middle stage HCC patients, with no severe adverse events and can effectively improve the overall survival time of patients.
